Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Go back to Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome| (NASDAQ: NGNE) | Delayed: 38.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.60 | 52 Week High | $ | |||
| Open | $38.60 | 52 Week Low | $ | |||
| Day High | $38.60 | P/E | N/A | |||
| Day Low | $38.60 | EPS | $ | |||
| Volume | 3 | |||||
